Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Descending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
10885-0001-01 10885-0001 Daunorubicin DaunoXome Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 13, 2012 April 16, 2016 No Longer Used
60505-3628-06 60505-3628 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3629-06 60505-3629 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3630-06 60505-3630 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3631-03 60505-3631 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3816-03 60505-3816 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
60505-3817-03 60505-3817 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0233-60 66993-0233 Dasatinib Dasatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0234-60 66993-0234 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0235-60 66993-0235 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0236-30 66993-0236 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0237-30 66993-0237 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0238-30 66993-0238 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
57894-0505-05 57894-0505 Daratumumab Darzalex IV 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Oct. 15, 2021 In Use
57894-0505-20 57894-0505 Daratumumab Darzalex IV 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Oct. 15, 2021 In Use
57894-0503-01 57894-0503 Daratumumab and hyaluronidase-fihj (human recombinant) Darzalex Faspro 1800.0 mg/15mL, 4.9 mg/15mL, 18.4 mg/15mL, 30000.0 U/15mL, 13.5 mg/15mL, 6.0 mg/15mL, 735.1 mg/15mL Immunotherapy Monoclonal Antibody CD38 Subcutaneous May 1, 2020 In Use
57894-0502-05 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov. 16, 2015 In Use
57894-0502-20 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov. 16, 2015 In Use
67457-0513-05 67457-0513 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Jan. 1, 2018 In Use
67457-0513-99 67457-0513 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Jan. 1, 2018 In Use
67457-0928-02 67457-0928 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous June 20, 2019 In Use
66993-0489-35 66993-0489 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Dec. 4, 2017 Nov. 30, 2024 In Use
42658-0008-01 42658-0008 Dactinomycin Dactinomycin 0.5 mg/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous May 8, 2024 In Use
71288-0129-02 71288-0129 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Nov. 13, 2020 In Use
59148-0046-70 59148-0046 Decitabine Dacogen 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 2, 2006 Aug. 31, 2024 In Use
62856-0600-01 62856-0600 Decitabine Dacogen 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 3, 1996 Dec. 31, 2018 No Longer Used
00703-5075-01 00703-5075 Dacarbazine Dacarbazine 200.0 mg/20mL Chemotherapy Alkylating Agent Purine Analog Intravenous Aug. 27, 1998 May 31, 2024 No Longer Used
00703-5075-03 00703-5075 Dacarbazine Dacarbazine 200.0 mg/20mL Chemotherapy Alkylating Agent Purine Analog Intravenous Aug. 27, 1998 Feb. 29, 2024 No Longer Used
61703-0327-22 61703-0327 Dacarbazine Dacarbazine 10.0 mg/mL Chemotherapy Alkylating Agent Purine Analog Intravenous Oct. 18, 2001 May 31, 2019 No Longer Used
63323-0127-10 63323-0127 Dacarbazine Dacarbazine 10.0 mg/mL Chemotherapy Alkylating Agent Purine Analog Intravenous Sept. 7, 2001 In Use
63323-0128-20 63323-0128 Dacarbazine Dacarbazine 10.0 mg/mL Chemotherapy Alkylating Agent Purine Analog Intravenous Sept. 7, 2001 In Use
71288-0174-21 71288-0174 Dacarbazine Dacarbazine 200.0 mg/20mL Chemotherapy Alkylating Agent Purine Analog Intravenous April 22, 2024 In Use
42858-0868-06 42858-0868 DRONABINOL DRONABINOL 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 26, 2018 In Use
42858-0867-06 42858-0867 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 26, 2018 In Use
42291-0449-60 42291-0449 dronabinol DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 16, 2020 In Use
42291-0450-60 42291-0450 dronabinol DRONABINOL 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 16, 2020 In Use
42291-0451-60 42291-0451 dronabinol DRONABINOL 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 16, 2020 In Use
42858-0869-06 42858-0869 DRONABINOL DRONABINOL 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 26, 2018 In Use
00904-6745-61 00904-6745 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 26, 2018 Jan. 31, 2023 No Longer Used
00904-6746-04 00904-6746 DRONABINOL DRONABINOL 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 26, 2018 Jan. 31, 2023 No Longer Used
60687-0375-01 60687-0375 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral July 16, 2018 Sept. 30, 2025 In Use
60687-0375-21 60687-0375 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral March 31, 2024 In Use
60687-0386-21 60687-0386 DRONABINOL DRONABINOL 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral Aug. 9, 2018 Oct. 31, 2025 In Use
60687-0386-94 60687-0386 DRONABINOL DRONABINOL 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 31, 2024 In Use
31722-0960-60 31722-0960 dronabinol DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral Feb. 10, 2020 In Use
31722-0961-60 31722-0961 dronabinol DRONABINOL 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral Feb. 10, 2020 In Use
31722-0962-60 31722-0962 dronabinol DRONABINOL 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral Feb. 10, 2020 In Use
00527-4125-35 00527-4125 Dronabinol DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral Feb. 10, 2020 In Use
49315-0008-03 49315-0008 Doxorubicin hydrochloride DOXORUBICIN HYDROCHLORIDE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Sept. 14, 2020 In Use
49315-0009-07 49315-0009 Doxorubicin hydrochloride DOXORUBICIN HYDROCHLORIDE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Sept. 14, 2020 In Use

Found 10,000 results in 11 milliseconds — Export these results